Hypothesis

Transient, immune‑targeted delivery of OSKM mRNA to senescent hematopoietic stem and progenitor cells (HSPCs) will rejuvenate mitochondrial function and suppress the pro‑inflammatory SASP, thereby breaking the feed‑forward loop in which immunosenescence drives systemic aging.

Mechanistic Rationale

Aged immune cells exhibit mitochondrial defects that increase ROS production and activate the NLRP3 inflammasome, amplifying IL‑1β and IL‑18 release (see [2]). This oxidative milieu reinforces p16^INK4a^ expression and IL‑6 secretion, creating a senescent environment that is permissive to OSKM‑mediated reprogramming ([7]). By preferentially transfecting senescent HSPCs with OSKM mRNA, we anticipate a rapid, transient activation of pluripotency factors that resets mitochondrial biogenesis via PGC‑1α upregulation without invoking HIF‑1α‑driven hypoxia ([88dded5b]). The resulting improvement in oxidative phosphorylation lowers ROS, dampens inflammasome signaling, and reduces SASP output. Because immune cells traffic throughout the body, their rejuvenated state curtails paracrine senescence induction in distant organs such as liver, kidney, and heart, as shown by Ercc1‑deficient hematopoietic transplants ([1]).

Testable Predictions

1. Mice receiving OSKM mRNA lipid nanoparticles targeted to CD45^+ cells will show a ≥30 % increase in HSPC mitochondrial membrane potential (JC‑1 ratio) within 7 days compared with saline controls.
2. Circulating levels of IL‑6, TNF‑α, and IL‑1β will drop by at least 25 % at 2 weeks post‑treatment and remain low for ≥8 weeks.
3. Histological analysis will reveal reduced fibrosis (collagen I area) and lower p16^INK4a^‑positive cell counts in liver, kidney, and heart tissues relative to untreated aged mice.
4. Functional readouts—grip strength, treadmill endurance, and vaccine‑induced antibody titers—will improve to levels comparable with young adult mice.
5. Transfer of treated immune cells into naïve young recipients will not induce premature organ senescence, whereas transfer of untreated aged immune cells will recapitulate the phenotype described in [1].

Experimental Design

• Animals: 20‑month‑old C57BL/6 mice (n=10 per group).
• Interventions: (a) OSKM mRNA‑LNP conjugated to anti‑CD45 antibody; (b) empty LNP control; (c) young (3‑month) baseline.
• Dosage: 2 µg total mRNA per mouse, intravenous, twice weekly for 3 weeks.
• Readouts: Flow cytometry for mitochondrial potential (MitoTracker Red), cytokine ELISA, qPCR for p16^INK4a^ and IL‑6, Sirius Red staining for fibrosis, functional assays as listed.
• Statistical plan: Power analysis targeting 80 % power to detect a 25 % cytokine change (α=0.05); ANOVA with Tukey post‑hoc.

Potential Implications

If validated, this approach would demonstrate that correcting a single driver—immune cell mitochondrial fitness—can delay multi‑organ aging, supporting a paradigm where immune rejuvenation precedes and potentiates other partial reprogramming strategies. It also suggests a clinically translatable route: mRNA‑LNP platforms already approved for vaccines could be repurposed for transient immune reprogramming with minimal off‑target effects.

References [1] https://doi.org/10.1038/s41586-021-03547-7 [2] https://doi.org/10.1126/science.aax0860 [3] https://www.jci.org/articles/view/64096 [4] https://med.stanford.edu/news/all-news/2024/03/older-immune-system.html [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC12659517/ [6] https://yangtan.mit.edu/new-study-suggests-a-way-to-rejuvenate-the-immune-system/ [7] https://doi.org/10.1111/acel.12711 [88dded5b] https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.944526/full